Cushing's Disease and the Pituitary: Causes, Diagnosis, and Treatment

What Is Cushing's Disease and How Does It Differ from Cushing's Syndrome?

Cushing's syndrome is the umbrella term for any state of chronic cortisol excess, regardless of origin. Cushing's disease refers only to the pituitary-dependent subtype, where a corticotroph adenoma drives the entire hormonal cascade. This distinction matters enormously for treatment planning, because removing the wrong target, such as an adrenal gland when the problem is actually in the pituitary, delays recovery by months or years.

Harvey Cushing first described the condition in 1932 after observing eight patients with basophilic pituitary adenomas and a constellation of features including central obesity, hypertension, and purple striae. His original case series remains one of the most cited documents in neuroendocrinology.

The Endocrine Society's 2015 Clinical Practice Guideline defines Cushing's syndrome as "the signs and symptoms associated with prolonged exposure to inappropriately high levels of plasma glucocorticoids" [1]. Pituitary-dependent disease is confirmed when ACTH is measurably elevated (typically above 20 pg/mL) and imaging or inferior petrosal sinus sampling localizes excess ACTH production to a pituitary source.

Causes of Cushing's syndrome break into three categories. First, ACTH-dependent causes include pituitary adenoma (Cushing's disease, roughly 70% of cases) and ectopic ACTH secretion from tumors such as small-cell lung carcinoma or bronchial carcinoid (roughly 10 to 15%). Second, ACTH-independent causes include primary adrenal adenoma or carcinoma (roughly 15 to 20%). Third, exogenous glucocorticoid use is the most common cause globally, but it is iatrogenic rather than endogenous.

How the HPA Axis Goes Wrong in Cushing's Disease

The hypothalamic-pituitary-adrenal (HPA) axis operates through a negative feedback loop. Normally, the hypothalamus releases corticotropin-releasing hormone (CRH), the pituitary responds by secreting ACTH, the adrenals produce cortisol, and rising cortisol suppresses further CRH and ACTH release. In Cushing's disease, the corticotroph adenoma continues secreting ACTH despite high cortisol levels. The feedback loop is not completely abolished, but the set point is shifted dramatically upward.

This explains a key diagnostic feature: in Cushing's disease, high-dose dexamethasone (8 mg) suppresses cortisol by at least 50% in roughly 80% of patients, because the tumor retains some glucocorticoid receptor sensitivity. In ectopic ACTH syndromes, suppression is almost never seen. Adrenal tumors show suppressed or undetectable ACTH with elevated cortisol, because the adrenal is functioning autonomously.

Sustained ACTH excess causes bilateral adrenal hyperplasia. Even after successful pituitary surgery, those hyperplastic glands may remain temporarily sluggish, producing a predictable post-operative state of secondary adrenal insufficiency. Patients require hydrocortisone replacement, typically 15 to 20 mg per day in divided doses, until the remaining normal corticotrophs recover, a process that can take 6 to 24 months [2].

Recognizing Cushing's Disease: Signs and Symptoms

The clinical picture of cortisol excess is broad. Central adiposity, moon facies, and a dorsocervical fat pad ("buffalo hump") are the most recognizable features, but none is pathognomonic on its own.

Specific features that raise suspicion above general obesity include wide (greater than 1 cm) purple-red striae on the abdomen or thighs, easy bruising with no trauma, proximal muscle weakness (patients struggle to rise from a chair without arm support), and hypertension that is resistant to two or more antihypertensive agents. In children, growth failure combined with weight gain is a red flag.

Psychiatric manifestations appear in up to 67% of patients with active Cushing's syndrome, most commonly depression, cognitive slowing, and irritability [3]. These symptoms often resolve with successful treatment, though recovery can lag behind cortisol normalization by 6 to 12 months.

Bone mineral density loss is nearly universal with prolonged hypercortisolism. A 2020 systematic review in the Journal of Clinical Endocrinology and Metabolism found vertebral fracture prevalence of 36 to 64% in active Cushing's syndrome, substantially higher than age-matched controls [4].

Laboratory abnormalities frequently include hypokalemia, hyperglycemia, and dyslipidemia. New-onset type 2 diabetes or rapid deterioration of existing glycemic control should prompt cortisol screening.

Diagnosing Cushing's Disease: The Step-by-Step Workup

Diagnosis follows a two-phase approach: first confirm hypercortisolism, then identify the source.

Phase 1: Confirm cortisol excess. The Endocrine Society recommends at least one of three first-line tests [1]:

1. Late-night salivary cortisol (collected at 11 p.m., when cortisol is normally at its nadir). Two elevated values (above 100 to 150 ng/dL, depending on the assay) are highly sensitive, around 93 to 100%.
2. Twenty-four-hour urinary free cortisol, with at least two collections above the upper limit of normal (roughly 50 to 100 mcg/24h on most immunoassay platforms, lower with mass spectrometry).
3. One mg overnight dexamethasone suppression test. A morning cortisol above 1.8 mcg/dL indicates failed suppression. Specificity is about 80%, so false positives from psychiatric illness, alcoholism, or obesity can occur.

A midnight serum cortisol above 7.5 mcg/dL in an inpatient setting is an alternative with high specificity.

Phase 2: Identify the source. Once hypercortisolism is confirmed, ACTH measurement separates ACTH-dependent from ACTH-independent disease. If ACTH is detectable or elevated, MRI of the pituitary with gadolinium contrast is performed. Because roughly 40 to 50% of corticotroph adenomas are smaller than 6 mm (microadenomas), MRI is negative in up to 40% of confirmed cases [5].

When MRI is negative or inconclusive, bilateral inferior petrosal sinus sampling (BIPSS) with CRH stimulation is the gold standard to confirm a pituitary source and lateralize the adenoma. A central-to-peripheral ACTH ratio above 2 at baseline, or above 3 after CRH injection, confirms pituitary origin with approximately 95% sensitivity and 100% specificity [6].

A practical decision framework used at HealthRX: if ACTH is above 20 pg/mL and MRI shows a lesion above 6 mm, proceed to surgery without BIPSS. If MRI is negative or the lesion is ambiguous, BIPSS is mandatory before any intervention. This threshold prevents unnecessary BIPSS in clear-cut cases while protecting patients with equivocal imaging from wrong-site surgery.

Treatment of Cushing's Disease: Surgery First, Then Second-Line Options

Transsphenoidal adenomectomy by an experienced neurosurgeon is the recommended first-line treatment. Remission, defined as a morning cortisol below 2 mcg/dL in the immediate post-operative period, is achieved in 65 to 90% of microadenomas and 50 to 60% of macroadenomas at high-volume centers [1].

Recurrence remains a significant concern. Among patients who achieve initial remission, approximately 20 to 25% relapse within 10 years, with rates as high as 35% at 15 years in some registry data [7]. These patients require continued annual surveillance with late-night salivary cortisol or 24-hour urinary free cortisol even after biochemical remission.

Medical therapy is used to control cortisol while awaiting surgery, when surgery is contraindicated, or after recurrence.

Steroidogenesis inhibitors reduce cortisol synthesis at the adrenal level. Metyrapone (500 mg to 4.5 g daily in divided doses) blocks 11-beta-hydroxylase and is effective in 75% of patients within days to weeks [8]. Ketoconazole (400, 1 to 200 mg daily) inhibits multiple steps in cortisol synthesis and is widely used outside the United States. Both require monitoring for adrenal insufficiency.

Osilodrostat (Isturisa), approved by the FDA in March 2020, is a more selective 11-beta-hydroxylase inhibitor. In the LINC 3 trial (N=137), osilodrostat normalized urinary free cortisol in 53% of patients at week 48 [9].

Pasireotide (Signifor), a somatostatin receptor ligand, targets the pituitary tumor itself rather than the adrenal. In a Phase 3 trial (N=162), pasireotide 900 mcg twice daily normalized urinary free cortisol in 26% of patients at 6 months [10]. Hyperglycemia occurs in up to 73% of patients and requires active glycemic management.

Mifepristone (Korlym) blocks the glucocorticoid receptor and is FDA-approved for hyperglycemia associated with Cushing's syndrome. Because it does not lower cortisol, monitoring is clinical rather than biochemical.

Radiation therapy, specifically stereotactic radiosurgery (Gamma Knife), is used when surgery fails or is not possible. Remission rates of 50 to 60% are reported, but the median time to remission is 18 to 36 months, and hypopituitarism develops in up to 50% of treated patients over 10 years [11].

Bilateral adrenalectomy is the definitive but last-resort option. It guarantees immediate resolution of hypercortisolism but creates permanent adrenal insufficiency, requiring lifelong glucocorticoid and mineralocorticoid replacement. An additional risk is Nelson's syndrome, in which the uncontrolled pituitary adenoma expands aggressively without adrenal feedback, occurring in 8 to 38% of patients post-adrenalectomy [12].

Addison's Disease: The Opposite Problem on the Same Axis

Where Cushing's disease represents cortisol excess, Addison's disease represents primary adrenal insufficiency, a failure of the adrenal glands themselves. The adrenal cortex is destroyed, most often by autoimmune attack (accounting for about 80% of cases in high-income countries), and production of both cortisol and aldosterone collapses [13].

Symptoms are the mirror image of Cushing's: fatigue, weight loss, hypotension, salt craving, and darkening of skin (hyperpigmentation) from ACTH excess, since the pituitary keeps signaling in the absence of feedback. ACTH rises above 200 pg/mL in most untreated cases, driving melanocortin-1 receptor stimulation and the characteristic bronze skin tone.

Diagnosis requires a morning cortisol below 3 mcg/dL, confirmed by a peak cortisol below 18 to 20 mcg/dL at 60 minutes after 250 mcg intravenous synthetic ACTH (cosyntropin stimulation test) [14].

Treatment is lifelong hormone replacement: hydrocortisone 15 to 25 mg daily in two or three divided doses (mimicking the physiological morning peak with a larger morning dose) and fludrocortisone 0.05 to 0.1 mg daily for mineralocorticoid replacement.

Secondary Adrenal Insufficiency: When the Signal Fails Before the Gland

Secondary adrenal insufficiency (SAI) occurs when ACTH secretion from the pituitary is inadequate, leaving the adrenal glands structurally intact but functionally dormant. The most common cause globally is abrupt discontinuation of exogenous glucocorticoids after prolonged use. A patient who has taken prednisone 10 mg daily for 6 months may take 6 to 12 months to recover normal HPA axis function after stopping [15].

Pituitary tumors, surgery, radiation, and traumatic brain injury are other causes. In the context of treated Cushing's disease, post-surgical SAI is expected and planned for.

Unlike Addison's disease, aldosterone secretion is preserved in SAI because the renin-angiotensin system controls mineralocorticoid production independently of ACTH. Hyponatremia still occurs due to cortisol deficiency (which normally suppresses ADH), but hyperkalemia and salt wasting are absent. Hyperpigmentation is also absent because ACTH levels are low rather than high.

The Endocrine Society guideline recommends cosyntropin stimulation testing 6 to 12 months after completing a glucocorticoid taper, or after pituitary surgery, to confirm axis recovery before discontinuing hydrocortisone replacement [14].

Adrenal Crisis: The Emergency Presentation

Adrenal crisis is an acute, life-threatening state of severe cortisol deficiency. It can occur in any patient with known or undiagnosed adrenal insufficiency, triggered by physiological stress: infection, surgery, trauma, vomiting, or even emotional distress. A 2015 European registry study found that adrenal crisis occurs at a rate of 6, 8 episodes per 100 patient-years in patients with established adrenal insufficiency, with a case fatality rate of approximately 6% per crisis episode [16].

Presentation includes profound hypotension, severe nausea or vomiting, abdominal pain, altered consciousness, and hyponatremia or hyperkalemia (in primary insufficiency). The clinical picture overlaps with sepsis, and delayed diagnosis is common.

Treatment must not wait for laboratory confirmation. Current guidelines from the European Society of Endocrinology and the Endocrine Society both recommend immediate administration of 100 mg hydrocortisone intravenous bolus, followed by 200 mg continuous infusion over 24 hours (or 50 mg every 6 hours intramuscularly if IV access is unavailable) [17]. One liter of 0.9% normal saline over the first hour addresses volume depletion.

Patients with known adrenal insufficiency should carry a medical alert bracelet and an emergency hydrocortisone injection kit (Solu-Cortef 100 mg Act-O-Vial). Sick day rules specify doubling or tripling the oral dose for febrile illness above 38°C (100.4°F) and administering parenteral hydrocortisone for any vomiting that prevents oral dosing.

As the Endocrine Society explicitly states in its 2016 Adrenal Insufficiency guideline: "Patients with adrenal insufficiency should be instructed to increase glucocorticoid doses during illness, injury, or surgery to prevent adrenal crisis" [14].

Monitoring After Treatment for Cushing's Disease

Post-operative monitoring is not optional. The American Association of Clinical Endocrinology (AACE) recommends measuring morning cortisol 24 to 48 hours after transsphenoidal surgery. A level below 2 mcg/dL strongly predicts remission. Levels above 5 mcg/dL in the first week suggest persistent disease.

Patients in biochemical remission require annual assessment with late-night salivary cortisol for at least 10 years given the recurrence rates above. Bone mineral density should be measured by DEXA scan at diagnosis and repeated 1 to 2 years post-treatment; trabecular bone recovers substantially within 12 to 24 months of sustained remission.

Cardiovascular risk does not fully normalize after cure. A retrospective cohort of 343 patients from the European Registry on Cushing's Syndrome (ERCUSYN) found that hypertension persisted in 32% and diabetes in 21% at 2 years post-remission, requiring ongoing cardiometabolic management [7].

Patients who underwent bilateral adrenalectomy need annual ophthalmology and pituitary MRI surveillance for Nelson's syndrome, with plasma ACTH measured at each visit.